Literature DB >> 29218108

The synergistic effect of esophageal squamous cell carcinoma KYSE150 cells and M2 macrophages on lymphatic endothelial cells.

Miao-Miao Sun1, Lu-Lu He2, Hong-Xin Zhang3,4, Na Wei3,4, Wei-Wei Wang3,4, Guo-Zhong Jiang3,4, Zheng-Yang Wang3,4, Dong-Mei Zhao1, Kui-Sheng Chen3,4.   

Abstract

Objective: This study aimed to investigate whether tumor-associated macrophages (TAMs) and esophageal squamous cell carcinoma (ESCC) cells could synergistically influence the generation of lymphatic vessels via the VEGF-C/VEGFR-3 signaling pathway and to address its mechanism.
Methods: M2 macrophages were sorted with immunomagnetic beads and induced in vitro. VEGF-C siRNA plasmids were constructed and transfected into M2 macrophages and the ESCC cell line KYSE150. Different conditioned culture media before and after transfection were collected and classified into different groups for culturing ESCC-associated lymphatic endothelial cells (ESCC-LECs). Using the CCK-8 assay, Transwell cell migration assay and Matrigel three-dimensional culture, the proliferation, migration and ring forming abilities of ESCC-LECs before and after transfection were compared, respectively. With ELISA, western blot and q(RT)-PCR, VEGF-C concentrations in conditioned culture media and the protein and mRNA expression levels of VEGFR-3 in LECs before and after transfection were compared, respectively.
Results: Before transfection, ESCC-LECs in the group with mixed culture medium had stronger proliferation, migration and ring forming abilities than the other groups. The VEGF-C concentration and VEGFR-3 protein and mRNA expression levels were higher in the mixed culture medium group than in the other groups. After transfection, all indices were the lowest in the mixed culture medium group. Conclusions: M2 macrophages can enhance the proliferation, migration and ring forming abilities of ESCC-LECs. ESCC cells and M2 macrophages have synergistic effects on the proliferation, migration and ring forming abilities of ESCC-LECs. VEGF-C siRNA can inhibit the proliferation, migration and ring forming abilities of ESCC-LECs by silencing the expression of VEGF-C and its receptor VEGFR-3 in KYSE150 cells and M2 macrophages.

Entities:  

Keywords:  RNA interference; TAMs; VEGF-C; esophageal squamous cell carcinoma-associated LECs; synergistic influence

Year:  2017        PMID: 29218108      PMCID: PMC5714794     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  23 in total

Review 1.  Proposed new lymphology combined with lymphatic physiology, innate immunology, and oncology.

Authors:  Toshio Ohhashi; Yoshiko Kawai
Journal:  J Physiol Sci       Date:  2014-11-07       Impact factor: 2.781

2.  VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway.

Authors:  Karine Villaume; Martine Blanc; Géraldine Gouysse; Thomas Walter; Christophe Couderc; Mimoun Nejjari; Cécile Vercherat; Martine Cordier-Bussat; Colette Roche; Jean-Yves Scoazec
Journal:  Neuroendocrinology       Date:  2010-04-13       Impact factor: 4.914

3.  Hyperplasia of lymphatic vessels in VEGF-C transgenic mice.

Authors:  M Jeltsch; A Kaipainen; V Joukov; X Meng; M Lakso; H Rauvala; M Swartz; D Fukumura; R K Jain; K Alitalo
Journal:  Science       Date:  1997-05-30       Impact factor: 47.728

4.  RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.

Authors:  Yukuan Feng; Jing Hu; Jing Ma; Kejian Feng; Xiaoli Zhang; Shucai Yang; Wei Wang; Jianguo Zhang; Yafang Zhang
Journal:  Eur J Cancer       Date:  2011-06-15       Impact factor: 9.162

5.  Total saponins of panaxnotoginseng promotes lymphangiogenesis by activation VEGF-C expression of lymphatic endothelial cells.

Authors:  Jinlong Li; Yan Chen; Li Zhang; Lianping Xing; Hao Xu; Yongjun Wang; Qi Shi; Qianqian Liang
Journal:  J Ethnopharmacol       Date:  2016-08-21       Impact factor: 4.360

6.  Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation.

Authors:  Maija Bry; Riikka Kivelä; Tanja Holopainen; Andrey Anisimov; Tuomas Tammela; Jarkko Soronen; Johanna Silvola; Antti Saraste; Michael Jeltsch; Petra Korpisalo; Peter Carmeliet; Karl B Lemström; Masabumi Shibuya; Seppo Ylä-Herttuala; Leena Alhonen; Eero Mervaala; Leif C Andersson; Juhani Knuuti; Kari Alitalo
Journal:  Circulation       Date:  2010-10-11       Impact factor: 29.690

7.  Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.

Authors:  Yulong He; Ken-Ichi Kozaki; Terhi Karpanen; Katsumi Koshikawa; Seppo Yla-Herttuala; Takashi Takahashi; Kari Alitalo
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

8.  Neuropilin-2 mediates lymphangiogenesis of colorectal carcinoma via a VEGFC/VEGFR3 independent signaling.

Authors:  Juan-Juan Ou; Xing Wei; Yuan Peng; Lin Zha; Rong-Bin Zhou; Hang Shi; Qi Zhou; Hou-Jie Liang
Journal:  Cancer Lett       Date:  2014-12-24       Impact factor: 8.679

9.  Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.

Authors:  Mitsuyuki Arinaga; Tsuyoshi Noguchi; Shinsuke Takeno; Masao Chujo; Takashi Miura; Yuzo Uchida
Journal:  Cancer       Date:  2003-01-15       Impact factor: 6.860

Review 10.  Role of hypoxia and vascular endothelial growth factors in lymphangiogenesis.

Authors:  Florent Morfoisse; Edith Renaud; Fransky Hantelys; Anne-Catherine Prats; Barbara Garmy-Susini
Journal:  Mol Cell Oncol       Date:  2015-05-27
View more
  1 in total

1.  Expression of vascular endothelial growth factor C in renal cell carcinoma and its correlation with pathological parameters and prognosis.

Authors:  Linna Shi; Ruihua Lv; Chen Li; Dong Han; Zhanli Ren; Ge Ren
Journal:  Transl Androl Urol       Date:  2020-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.